Clinical Trial Update: Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing concurrent chemoradiotherapy with anlotinib for unresectable stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN